Our preclinical study aims to analyze the biodistribution of a newly developed 68Ga-labeled radiopharmaceutical, [68Ga]Ga-NODAGA-Z360, in an animal model with a human epidermoid carcinoma A431 cell line overexpressing CCK2R (A431 CCK2R+). Here, CCKBR is linked to squamous cell carcinoma.